Find out more at btsub.sg/btdeal
You are here
Gilead ordered to pay Merck US$200m for hepatitis C patents
GILEAD Sciences Inc was ordered by a jury to pay Merck & Co US$200 million for patent infringement over a drug compound that cures hepatitis C, a tenth of what Merck sought.
The verdict announced on Thursday follows an earlier finding by the jury embracing Merck's
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org